These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38182995)

  • 1. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
    Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
    BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
    Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
    BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
    Liu Y; Wang W; Yin R; Zhang Y; Zhang Y; Zhang K; Pan H; Wang K; Lou G; Li G; Zhang R; Li K; Rao J; Zhang B; Wang Y; Wang Q; Gao Y; Li H
    BMC Med; 2023 Sep; 21(1):376. PubMed ID: 37775744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting.
    Zhang R; Chen Y; Liu X; Gui X; Zhu A; Jiang H; Shao B; Liang X; Yan Y; Zhang J; Song G; Li H
    Front Oncol; 2023; 13():1076469. PubMed ID: 37397355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study.
    Huang W; Wang C; Wang L; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
    Front Cell Dev Biol; 2024; 12():1313610. PubMed ID: 38481526
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and Safety of Third-Line Apatinib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer Patients: A Multicenter, Retrospective, Cohort Study.
    Fan W; Ding J; Zhong W
    Tohoku J Exp Med; 2023 May; 260(1):13-20. PubMed ID: 36696982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
    Nie C; Lv H; Chen B; Xu W; Wang J; Wang S; Liu Y; He Y; Zhao J; Chen X
    Technol Cancer Res Treat; 2023; 22():15330338221150561. PubMed ID: 36632666
    [No Abstract]   [Full Text] [Related]  

  • 9. The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer.
    Huang JY; Chen XL; Xie XF; Song L; Chen LP; Lan XF; Bai X; Chen X; Du CW
    Cancer Med; 2024 Apr; 13(8):e7181. PubMed ID: 38659376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
    Zhang Q; Shao B; Tong Z; Ouyang Q; Wang Y; Xu G; Li S; Li H
    BMC Med; 2022 Oct; 20(1):321. PubMed ID: 36184642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
    Hu X; Zhang J; Xu B; Jiang Z; Ragaz J; Tong Z; Zhang Q; Wang X; Feng J; Pang D; Fan M; Li J; Wang B; Wang Z; Zhang Q; Sun S; Liao C
    Int J Cancer; 2014 Oct; 135(8):1961-9. PubMed ID: 24604288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of neoadjuvant apatinib in combination with dose-dense paclitaxel and carboplatin in locally advanced triple negative breast cancer patients].
    Ou KP; Li Q; Luo Y; Lyu JJ; Zhou H; Yang Y; Cai YJ; Wang ZJ; Wang X; Qi LQ; Ma F; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):966-971. PubMed ID: 33256310
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
    Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
    Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study.
    Du Y; Cao Q; Jiang C; Liang H; Ning Z; Ji C; Wang J; Zhou C; Jiang Z; Yu C; Li L; Zhao Y; Xu Y; Xu T; Hu W; Wang D; Cheng H; Wang G; Zhou J; Wang S; Zhang Y; Hu Z; Li X; Lu D; Zhang J; Xie H; Sun G
    Cancer Med; 2020 Jul; 9(14):5008-5014. PubMed ID: 32441892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases.
    Chen X; Bai X; Xie X; Huang J; Chen L; Song L; Lan X; Zhang Q; Guo J; Du C
    Ann Med; 2023 Dec; 55(1):2218647. PubMed ID: 37260331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting.
    Leng J; Li DR; Huang LM; Ji XH; Wang DL
    Medicine (Baltimore); 2019 Sep; 98(36):e16967. PubMed ID: 31490378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study.
    Ni M; Zhou L; Lu Y; Guo D; Li X; Li L; Zhang L; Chen M; Zhang L; Xu F; Yuan Z; Wang S; Shi Y; Yang A; An X
    BMC Cancer; 2024 Sep; 24(1):1214. PubMed ID: 39350055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial.
    Li DD; Tao ZH; Wang BY; Wang LP; Cao J; Hu XC; Zhang J
    NPJ Breast Cancer; 2022 Sep; 8(1):110. PubMed ID: 36127351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial.
    Wu S; Zhang L; Li H; Xu J; Jiang C; Sun T
    Trials; 2020 May; 21(1):420. PubMed ID: 32448335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].
    Ye T; Yuan SY; Fan L; Feng LW; Chen YT; Chen J
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2435-2440. PubMed ID: 36000372
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.